Loading
A phase 1/2 trial of Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib and Capivasertib in advanced solid tumours, run by Stemline Therapeutics, Inc., active and no longer recruiting.
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT05563220 by Stemline Therapeutics, Inc., with 435 participants enrolled, started 2023-01-24 and due to reach its primary completion in 2026-12-27. Interventions recorded: Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib and Capivasertib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, UCSF Helen Diller Family Comprehensive Cancer Center, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Capivasertib, Palbociclib, UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Everolimus, Palbociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, UCSF Helen Diller Family Comprehensive Cancer Center, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ribociclib, Palbociclib, UCSF Helen Diller Family Comprehensive Cancer Center, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/